Adrian Rawcliffe
2016
In 2016, Adrian Rawcliffe earned a total compensation of $1.3M as Chief Financial Officer at Adaptimmune Therapeutics, a 57% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $117,450 |
|---|---|
| Option Awards | $674,104 |
| Salary | $435,000 |
| Other | $34,262 |
| Total | $1,260,816 |
Rawcliffe received $674.1K in option awards, accounting for 53% of the total pay in 2016.
Rawcliffe also received $117.5K in non-equity incentive plan, $435K in salary and $34.3K in other compensation.
Rankings
In 2016, Adrian Rawcliffe's compensation ranked 7,131st out of 14,075 executives tracked by ExecPay. In other words, Rawcliffe earned more than 49.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,131 out of 14,075 | 49th |
Division Manufacturing | 2,686 out of 5,489 | 51st |
Major group Chemicals And Allied Products | 877 out of 1,895 | 54th |
Industry group Drugs | 677 out of 1,538 | 56th |
Industry Biological Products, Except Diagnostic Substances | 119 out of 279 | 57th |
Source: SEC filing on April 28, 2017.
Rawcliffe's colleagues
We found three more compensation records of executives who worked with Adrian Rawcliffe at Adaptimmune Therapeutics in 2016.